Rare Thyroid Therapeutics International AB

Egetis Therapeutics is a specialty pharmaceutical company focused on developing and commercialising treatments for serious rare diseases with high unmet medical need. Its work includes tiratricol (Emcitate), a treatment for MCT8 deficiency, and research related to other rare thyroid hormone disorders. The company’s website reports a U.S. launch of Emcitate in October 2026.